Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A new antigen termed PTA (plasmocytoma thymus antigen) is described which occurs on 70--80% of mouse thymocytes of all mouse strains tested and on an IgG 2b producing BALB/c plasma cell
tumor
. PTA is detectable on mouse spleen and lymph node cells. It is absent from liver, brain, bone marrow, and antibody
plaque
forming cells. PTA is not related to theta antigen and is not detectable on rat thymocytes.
...
PMID:Detection of a cell surface antigen common to a mouse myeloma and a population of mouse thymocytes. 38 23
A non species specific lymphocyte differentiation antigen is described which can be detected on
plaque
forming cells and a small fraction of thymocytes of mice and rats. The antigen is absent from a BALB/c plasma cell
tumor
and is not detectable on Dexamethasone-resistant thymocytes. On the basis of its occurrence the term TPCA (thymus plasma cell antigen) is proposed for the antigen. A monospecific anti TPCA serum could be prepared which enables the detection of the antigen on about 10% of rat thymocytes.
...
PMID:A common differentiation antigen on plaque forming cells and a subpopulation of thymus cells in mice and rats. 38 24
Three types of cell mosaics have been used in mammalian studies: hemopoietic shimeras, mosaics formed by aggregation of preimplatation embryos, and mosaics resulting from X-chromosome inactivation. The problems investigated with these cell mosaics have included normal tissue orgaization, cell selection, primordial cell pool sizes, and
tumor
cell kinetics. The emphasis in this review is on the application of X-chromosome inactivation mosaics to the analysis of
tumor
cell proliferation. The first application of mosaicism to
tumor
ontogeny involved leiomyomas and demonstrated single cell and independent origin of the tumors. Other
tumor
studies are reviewed including those of presumed multiple cell origin, especially those of hereditary origin and viral etiology. The concept of target size is invoked to explain these multiple cell origin tumors. The recent reports on the clonal nature of atherosclerotic plaques is also discussed. Emphasis is placed on resolving the relationship between the multiclonal underlying fatty streak and the clonal
plaque
in order to understand the implications of the clonal plaques.
...
PMID:Patterns of cellular proliferation in normal and tumor cell populations. 40 17
Mycosis fungoides is a cutaneously-derived malignant lymphoma which, without effective treatment, may run an unrelenting, rapidly lethal course. Often beginning as a nonspecific skin eruption, easily misdiagnosed as a common eczema or psoriasis, the disease progresses through a
plaque
stage to the
tumor
stage with the appearance of the mushroom-like growths for which the entity was originally named. Because of the dismal outlook in uncontrolled cases, newer, more aggressive approaches to therapy are being developed and are being instituted earlier in the course of the disease.
...
PMID:Mycosis fungoides: clinical and therapeutic review. 42 72
A 3-year followup on ten of 12 patients with mycosis fungoides (MF) treated with photochemotherapy (PUVA; psoralens + ultraviolet light) reveals eight patients whose diseases have remained clear while receiving maintenance PUVA. An additional 35 patients with MF have been successfully treated with PUVA. Eight cases of parapsoriasis en
plaque
have cleared with PUVA. PUVA is indicated in early eczematous and
plaque
stages of MF. It may be used as adjunctive therapy in
tumor
-stage MF treated with X-ray therapy or chemotherapy.
...
PMID:Photochemotherapy for mycosis fungoides: long-term followup study. 44 19
Murine teratocarcinoma stem cells are nonpermissive for productive infection by a variety of DNA (polyoma and SV40 virus) and RNA (murine leukemia and sarcoma virus)
tumor
viruses whereas differentiated murine cells derived from the stem cells are permissive for productive (or abortive in the case of SV40) infection by these same viruses. The block to productive infection by these oncogenic viruses is at a postpenetration step in the replication cycle of these viruses but the precise level of the block has not been established for any of these viruses. In this report we describe teratocarcinoma-derived stem and differentiated cell lines which should be especially useful in determining the level of the block to replication of ecotropic murine leukemia virus in murine teratocarcinoma stem cells. The stem cell line, OTT6050AF1 BrdU, which is completely nonpermissive to productive infection by Moloney murine leukemia virus and consists of 97% pluripotent stem cells, contains DNA copies of an RNA
tumor
virus which is indistinguishable from the N-tropic murine leukemia virus of AKR mice. The stem cells are negative for expression of viral reverse transcriptase, p30 and gp69/71 and no virus is found by XC
plaque
assay or other biological tests. Differentiated cells established from the same teratocarcinoma
tumor
are 100% positive for viral gp69/71, p30, and produce large amounts of reverse transcriptase activity and N-tropic virus as detected by biological assay. The virus isolated from the differentiated cells is closely related, if not identical to AKR N-tropic virus by nucleic acid hybridization studies and is thus not an endogenous virus of the 129 strain of mice. The teratocarcinoma
tumor
from which the cell lines were established had been carried in 129 mice and perhaps at some time in the mouse passage history the tumors were infected (nonproductively) with the N-tropic virus. Regardless of the origin of this viral DNA, the OTT6050A derived stem and differentiated cell lines should be extremely useful in defining in stem cells the step at which ecotropic murine leukemia virus replication is blocked.
...
PMID:A murine teratocarcinoma stem cell line carries suppressed oncogenic virus genomes. 45 80
A rare case of an epithelioid sarcoma of the penis arising as a superficial
plaque
in the glans and causing pain on erection is reported. This
tumor
is characterized by a slow growth and infiltrative pattern with a high propensity for local recurrence. Proper treatment is wide local excision.
...
PMID:Epithelioid sarcoma of penis. 47 73
A 59-year-old black woman presented with an ill-defined
plaque
on her nose. This appeared clinically suggestive of a sclerosing type of basal cell epithelioma (BCE). Microscopic sections demonstrated this diagnosis. Multiple excisions employing the microscopically controlled technique of Mohs traced the
tumor
deep into the nasal cartilage before histologic sections were free of
tumor
cells. This type of BCE deserves well planned therapy because of its destructive potential.
...
PMID:Mutilating sclerosing basal cell epithelioma. 49 81
A unique case of multiple keratoacanthomas is described, with involvement of the face and lower extremities with persistent lesions clinically and histologically diagnostic of keratoacanthomas. The lower extremity lesions appear as giant keratoacanthomas, with evolution into a distinctive confluent
plaque
. This important
tumor
and its present classification are reviewed.
...
PMID:Multiple persistent keratoacanthomas. 51 90
Mycosis fungoides is a T-cell lymphoma which is often localized to the skin in the early stages. Untreated, the process eventually progresses through eczematous,
plaque
, and
tumor
stages to systemic involvement. Its course, however, is unpredictable. Topical chemotherapy is effective in early stages of mycosis fungoides. Possibly prognostic benefits can occur from the early use of these agents. Nitrogen mustard and BCNU, both alkylating agents, have been used topically to control the disease. A dermatitis may develop in persons treated with nitrogen mustard but systemic side-effects are rare. However, BCNU may rarely lead to marrow depression when used topically. The use of these agents in mycosis fungoides is discussed herein.
...
PMID:Topical chemotherapy of mycosis fungoides. 52 32
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>